Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

@article{Rivera2009TreatmentOA,
  title={Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.},
  author={F Rivera and Sara L{\'o}pez-Tarruella and Ma Eugenia Vega-Villegas and M Casado Salcedo},
  journal={Cancer treatment reviews},
  year={2009},
  volume={35 4},
  pages={335-9}
}
The prognosis of advanced pancreatic adenocarcinoma is still poor nowadays. Gemcitabine in monotherapy (30-min infusion) has been the standard of treatment during the last decade, and many clinical trials have failed to demonstrate an improvement in overall survival (OS) with the addition of different drugs to gemcitabine, including cetuximab and bevacizumab. Nevertheless, some modest but interesting advances have been provided by combinations such as gemcitabine-erlotinib, gemcitabine… CONTINUE READING

From This Paper

Topics from this paper.
52 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 52 extracted citations

Similar Papers

Loading similar papers…